Mounjaro FAQs

Mounjaro (tirzepatide) is a once-weekly injection that acts on GIP and GLP-1 receptors to help reduce appetite and support weight loss alongside diet and activity.

NICE recommends tirzepatide for eligible adults with obesity and weight-related health problems, with implementation guidance for primary care and specialist services.

Yes—clinicians can prescribe privately if you meet the licensed criteria after assessment. UK licensing covers adults with BMI ≥30, or ≥27 with weight-related comorbidity.

It’s injected once weekly with gradual dose increases per your prescriber, using a KwikPen device.

Take the missed dose as soon as possible within 4 days (96 hours). If more than 4 days have passed, skip it and take your next dose on your usual day. Don’t take 2 doses within 3 days.

Under the skin of the stomach, thigh, or upper arm—rotate sites weekly.

Common: nausea, vomiting, diarrhoea/constipation, reduced appetite. Get urgent advice for severe abdominal pain (possible pancreatitis) or gallbladder symptoms. Regulators also remind clinicians and patients to be alert to misuse and to report side effects.

Your prescriber will screen for contraindications and interactions. Always follow the UK patient leaflet and medical advice.

There’s no blanket prohibition, but alcohol can aggravate GI side effects and may hinder weight-loss goals—moderation is usually advised.

Not recommended; discuss contraception, family planning, and breastfeeding with your clinician and review the leaflet.

Follow the pen leaflet’s temperature guidance (typically refrigerate before first use; there are specific rules after first use and for travelling).

Results vary by dose and adherence to lifestyle changes. NHS/NICE guidance emphasises ongoing monitoring within a weight-management plan.

Switching requires clinical oversight and a gap (washout) between medicines; your prescriber will plan timing and starting dose.